LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Maintains Target Price $3
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
Positive Outlook for ALX Oncology: Buy Rating Backed by Promising Clinical Data and Strong Financials
ALX Oncology Holdings Analyst Ratings
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $25
Maintaining Buy Rating on ALX Oncology: Promising Clinical Data and Anticipated Progress of Evorpacept
ALX Oncology Holdings Analyst Ratings
ALX Oncology Holdings Analyst Ratings
ALX Oncology Holdings Analyst Ratings
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Cuts Target Price to $5
Stifel Nicolaus Remains a Hold on ALX Oncology Holdings (ALXO)
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $25
Promising Future for ALX Oncology's Evorpacept: A Buy Rating Justified by Clinical Trials and FDA Prospects
ALX Oncology Holdings Analyst Ratings
ALX Oncology Holdings Analyst Ratings
Buy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial Results
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Piper Sandler Sticks to Its Buy Rating for ALX Oncology Holdings (ALXO)
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)